 |
|
August 4, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
CEO WEEKLY Q&A:
Todd Dickinson, President & CEO,
Stellaromics |
| In this
Q&A, Dickinson explains why
conventional spatial platforms lose
critical biological information by cutting
tissue too thin, how its Pyxa® platform
preserves native tissue architecture in
sections up to 100 microns thick, and what
that means for drug discovery, tumor
biology, and patient care. More |
|
|
- Acurx: FDA Provides Further Regulatory
Guidance for the Ibezapolstat Clinical
Development Program, Including the Potential
for a Single-Phase 3-Trial Registration Plan
and a Trial Design to Support Both Treatment
and Reduction of Recurrence of C. difficile
Infection More
- Adlai Nortye: Clinical Trial Notification
Submission and HREC Approval for the Phase I
Clinical Trial of Pan-RAS(ON) Inhibitor ADC
AN4035 in Australia More
- Dianthus Therapeutics: DNTH312, a
First-In-Class, Next-Generation Bifunctional
Fusion Protein Combining Claseprubart and
TACI, for Severe Autoimmune Diseases More
- Dr. Reddy: First-to-Market Launch of
Sugammadex Injection 200 mg/2 mL (100 mg/mL)
and 500 mg/5 mL (100 mg/mL) Single-Dose Vials,
a Generic Equivalent of Bridion, in the United
States More
- Intelligent Bio Solutions: Completes
Interference Study Examining the Impact of
Everyday Substances on Intelligent
Fingerprinting System
More
- Otsuka: Unveils Unprecedented Phase
3 VISIONARY Two-Year eGFR Results
Demonstrating VOYXACT (sibeprenlimab-szsi)
Stabilizes Kidney Function Decline to
Baseline Physiologic Rate, Fundamentally
Altering Disease Progression in IgA
Nephropathy (IgAN) More
More*
- Pathos AI: Enters Collaboration and
Co-Exclusive Licensing Agreement to Advance
Novel ERα PROTAC for ER+ Breast Cancer into
the Clinic More
More*
- Pathos AI: Enters Global Licensing
Agreement With Alphamab Oncology on JSKN016,
a First-in-Class TROP2/HER3 Bispecific ADC More
More*
|
|
- Definium Therapeutics: New
Employee Inducement Grants More
- Dianthus Therapeutics: Inducement Grants
Under NASDAQ Listing Rule 5635(C)(4)
More
- Henry Schein: Strong Second Quarter 2026
Financial Results and Raises FY2026 Guidance More
- Lisata Therapeutics: Update Following
Termination of Merger Agreement More
- Merck: Second-Quarter 2026 Financial
Results; Highlights Key Regulatory and
Clinical Milestones Across Broad, Diverse
Pipeline More
More
More*
More*
- More on AstraZeneca-Bristol Myers Megamerger
Talk Leaving Wall Street Wanting More Answers
More*
More
More
More
- Pfizer: Second-Quarter Results and Raises
Midpoint of 2026 Revenue Guidance More
More*
|
|
- Big4Bio CEO Weekly Q&A: Todd
Dickinson, President & CEO, Stellaromics
More
- Biotech Hangout: Episode 191
Podcast
- More on Rocket Pharmaceuticals Touting
Positive Early Safety Data From Revised
Genetic Therapy Trial
More
More*
- Slone Partners: Premier Executive
Search and Talent Advisory Firm More
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
- Helus Pharma: Appoints Michael
Halstead as Chief Executive Officer More
- OPPORTUNITY: Chief Scientific Officer,
Manassas, VA
More
- OPPORTUNITY: President, PA More
- OPPORTUNITY: Vice President, Global BD,
Remote More
- Slone Partners: Places Amer Mirza, PhD, as
Chief Scientific Officer at Prolynx More
- Slone Partners: The Convergence of
MedTech and Digital Health - How New Hybrid
Devices Are Reshaping Care Delivery and
Leadership Profiles More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: NYC Life Science Company
Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:NYC,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
